#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Demyelination Alport's syndrome Pyruvate kinase deficiency anaemia Craniopharyngioma Marginal zone lymphoma refractory Meningitis meningococcal Paraneoplastic neurological syndrome Synovial sarcoma Acquired ATTR amyloidosis Hidradenitis Anaplastic large cell lymphoma T- and null-cell types Heritable pulmonary arterial hypertension Breast angiosarcoma metastatic Bronchopulmonary dysplasia Microvillous inclusion disease More trials…

    Learn about Rare Diseases

    Fabry’s disease Soft tissue sarcoma Brain stem glioma – Basic Information Chronic granulomatous disease – Diagnostics Acquired haemophilia Nephrotic syndrome – Diagnostics Rosai-Dorfman syndrome – Trials in Disease Mast cell activation syndrome – Trials in Disease Breast angiosarcoma – Diagnostics Brain stem glioma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sodium Nitrite Lysine Aspirin Iopamidol Ab-1002 Oric-114 Lidocaine Hydrochloride Water For Injection PRILOCAINE HYDROCHLORIDE Alxn1850 Gskvx000000014593 Pentetic Acid N-Acetylhistidine Specific Nucleic Acid Sna-Papi Raxtozinameran Nilutamide Trifluridine Rezvilutamide L-PHENYLALANINE 18F-Psma-1007 Taurine More therapies…

    Learn about Your Condition

    Fallopian tube cancer stage IV Splenic marginal zone lymphoma Labour induction Dermatitis atopic Biliary neoplasm Epicondylitis Sickle cell disease Non-obstructive cardiomyopathy Benign renal neoplasm Univentricular heart Haemoglobinuria Erdheim-Chester disease Cytokine release syndrome Diarrhoea Optic atrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Crohn’s disease

  • Study of SAR441566 compared to placebo for adults with moderate to severe Crohn’s disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Bulgaria Croatia Czechia France Germany Hungary +5

  • Study on the Safety and Effectiveness of Adalimumab as Initial Treatment for Newly Diagnosed Crohn’s Disease Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Adalimumab
    The Netherlands

  • Study on the Safety and Effects of ORG-129 in Patients with Fibrostenotic Crohn’s Disease

    Not recruiting

    2 1
    Investigated Drugs:
    • ORG-129
    Austria Denmark Germany Italy Poland Spain

  • Study on Risankizumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Drugs:
    • Risankizumab
    Czechia Hungary Lithuania Poland

  • Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Bi 706321
    • Ustekinumab
    Czechia Germany Hungary Italy Poland Spain

  • Study on Guselkumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    Croatia Czechia France Germany Hungary Italy +4
Previous Page
1 … 9 10 11 12 13 … 16
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!